About

Mighty Capital is a Silicon Valley venture capital firm that invests in companies building “products that count:” products that transform lives and create value at scale.
  • Portfolio companies say that we bring the “best value for the dollar invested”
    • We co-invest with top VCs at later stage
    • We are committed to being the most helpful investor you will ever have
  • The unique value we bring to our portfolio is:
    • The combination of handpicked Silicon Valley investors, and
    • Proprietary access to one of the largest networks of product managers in the world (>200,000 product managers), which can become hires, customers, and more
Our investment criteria are:
  • Demonstrated evidence of product/market fit,
  • Amazing CEO and Bay-Area-based leadership,
  • Not the first money in –previous funding or revenue traction.
If you or someone you know runs a company that meets those criteria, we’d love to hear about it! The best way to get in touch with us is via a mutual connection, most likely a current investor or your law firm. If that’s not an option, then email dealflow@mighty.capital.

Blog


September 4, 2017

A killer pitch deck sounds like a story by design. It is meant to help you step back from the details of your business or new product, to tell a compelling story to an investor. It reads as simple as this: “We are a unique team, excited to solve a big and hard problem. We came up with a sustainably differentiated solution. As a result, we are gaining solid traction, which we monetize fairly. So our financials look extremely promising but to get there, we need a reasonable amount of funding. We have a credible plan to generate significant returns for our investors.”

Read More

February 3, 2017

When a due diligence is appropriate, we ask the entrepreneur to make a data room available to the due diligence team. Through a review of the material in the data room and discussions with the CEO, exec team and references, the due diligence lead is able to cover the key aspects of the due diligence: team, business, financing, and match with Mighty Capital.

Read More

April 12, 2019

Mighty Capital, whose founder and managing partner is SC Moatti, has its first liquidity event. SC tells Women’s PE Briefs that the firm sold a small portion of its first investment, Amplitude.

Read More

April 12, 2019

Hear from the leader as one of Mighty Capital’s portfolio companies share his experience delivering customer delight through product:

  • The power of authentic customer delight
  • Driving efficiencies for growth with a personal touch
  • Staying true to your company’s mission and core values

To effectively scale a business, it’s critical to focus on providing customer delight with marketing tactics that are rooted in the product’s core value.

Read More

April 4, 2019
Idea to IPO’s mission is to promote entrepreneurship, support entrepreneurs, build community, & provide value in the Silicon Valley startup ecosystem.
SC Moatti participated as a panelist during the 2/28/2019 Venture Capital Panel discussing the hottest funding trends of 2019.
Read More

March 29, 2019

Following earlier LabCorp strategic investment, Mission Bio single cell-sequencing technology will be used by LabCorp to support clinical trials, along with the evaluation of potential applications in clinical diagnostics and companion diagnostics development.

Read More

February 21, 2019

Our Managing Partner SC Moatti wrote an editorial for Barron’s discussing the impact of mega-funds on the rest of the venture capital ecosystem. Here’s an abstract: In venture capital, the assumption used to be that to survive against the likes of Sequoia and the Vision Fund, funds need to get big. Really big. However, it’s become nearly impossible to remain competitive in the go-big-or-go-home scenarios. It’s no longer a winner-take-all market. The insightful, agile, lateral looking investor, however, has plenty of room to move and grow into the future. For the shrewd venture investor, new strategies—ones that leverage inherent ecosystem value —make the most sense.

Read More

February 21, 2019

Having insights into how investors think about assessing a startup team will also help you think about designing your organization and hiring for the right qualities. I’ll break down the questions investors may ask themselves into 4 easy to remember categories.

Read More

February 7, 2019

HYP3R is leading the transformation of location marketing to deliver experiences that are delightful and effective. HYP3R’s innovations in location marketing cloud help top marketers acquire and engage high-value customers in the real world through digital experiences that are surprisingly human. At the core of HYP3R is a unique dataset of hundreds of millions of the highest value consumers in the world that gives an edge to the leaders in travel and retail. HYP3R, one of Fast Company’s Most Innovative Companies, was founded in 2015 and is based in San Francisco. Learn more at https://hyp3r.com or follow @HYP3R on Twitter.

Read More

February 6, 2019

As a technology investor, I meet a wide variety of entrepreneurs and startup founders. Many times I’ll ask them, “Why do you do what you do? What’s your endgame?” Many of them share their passion for the journey or how much they value the freedom to be their own boss. Others find it rewarding that they create jobs. For the savvy entrepreneur, however, a big part of their answer includes a fully developed exit strategy. So please, eat healthy, exercise and hug your loved ones. Take care of your body, mind and spirit. And while you’re at it, write down your exit strategy.

Read More

January 2, 2019

The stock market turmoil of December 2018 reminds us to never take anything for granted. Still, good investment opportunities exist if you know where to look. My expectation is that 2019 will see significant private equity and venture capital activity thanks to multiple economic factors including a solid M&A appetite.

Read More

December 14, 2018

Mission Bio delivers targeted single-cell genomics solutions for high-impact applications with Tapestri, the Precision Genomics Platform. Tapestri is the industry’s first targeted single-cell DNA sequencing platform, enabling precise detection of heterogeneity in disease progression and treatment response. Application areas include blood cancers, solid tumors, and genome editing validation. The platform includes an instrument, consumables, and analysis software, which integrate seamlessly with existing NGS workflows. With Tapestri, researchers have a highly sensitive, targeted, and customizable solution to move precision medicine forward.

Read More

© 2019 Mighty Capital All Rights Reserved